Wondering if Regeneron Pharmaceuticals is a hidden gem or just fairly priced? You are not alone; investors everywhere are ...

According to Benzinga Pro, Regeneron Pharmaceuticals Inc's peer group average for short interest as a percentage of float is ...

A patient dosed with Intellia Therapeutics’ CRISPR gene therapy has died after suffering a severe liver-associated adverse ...

Merck said Saturday its new pill — a potential rival to Regeneron and Amgen — lowered stubbornly high cholesterol by almost ...

Equities broadly ended higher, with some reaching record levels, contributing to strong year-to-date performance. Read more ...

As of Friday, November 07, CytomX Therapeutics, Inc.’s CTMX share price has dipped by 18.38%, which has investors questioning ...

Learn more about whether BioMarin Pharmaceutical Inc. or Ultragenyx Pharmaceutical Inc. is a better investment based on ...

iShares Biotechnology ETF (IBB) offers targeted exposure to the U.S. biotechnology sector, providing investors with access to a broad basket of industry-leading biotech equities. The fund's strategy ...

Investors in Intellia Therapeutics are bracing for impact as the biotech firm faces one of its most significant challenges to ...

Shares of Regeneron Pharmaceuticals Inc. REGN rallied 2.58% to $644.19 Wednesday, on what proved to be an all-around great ...

Regeneron and Sanofi’s Dupixent trial shows major improvement in allergic fungal rhinosinusitis symptoms in patients 6+. Read ...

The sessions may be accessed from the "Investors & Media" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays and transcripts of the webcasts will be ...